Skip to content

Study · Systematic review · 2024

8 results

Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.

Cao A, Feng F, Zhou X

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP1 Dec 2024Cited by 1 (Europe PMC)

PMID39648386 (opens in a new tab)DOI10.29271/jcpsp.2024.12.1497 (opens in a new tab)PepBankPUB-39648386
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with acute exacerbation of COPD, thymosin alpha‑1 plus routine treatment significantly improved FEV1 compared with routine treatment only.

    In plain wordsIn people with a COPD flare-up, thymosin alpha‑1 added to routine care improved lung function (FEV1) more than routine care alone in pooled trials.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseForced expiratory volume in 1 second (FEV1)
    Study

    n: not reported in source

    Comparator
    Routine treatment only
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated

    Measurements

    MD
    0.29
    FEV1

    Source sentences

    Summary
    significantly improved forced expiratory volume in 1 second [MD = 0.29, 95% (0.26, 0.32), p <0.001]
    1 context sentence
    Summary · context
    Thirty-nine randomised controlled trials with a total of 3,329 patients were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In patients with acute exacerbation of COPD, thymosin alpha‑1 plus routine treatment significantly improved the FEV1/FVC ratio compared with routine treatment only.

    In plain wordsIn people with a COPD flare-up, thymosin alpha‑1 added to routine care improved a lung function ratio more than routine care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseFEV1/FVC ratio
    Study

    n: not reported in source

    Comparator
    Routine treatment only
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated

    Measurements

    MD
    6.24
    FEV1/FVC

    Source sentences

    Summary
    the ratio of forced expiratory volume in the first second to forced vital capacity [MD = 6.24, 95% (3.83, 8.65), p <0.001]
    1 context sentence
    Summary · context
    Thirty-nine randomised controlled trials with a total of 3,329 patients were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In patients with acute exacerbation of COPD, thymosin alpha‑1 plus routine treatment increased arterial partial pressure of oxygen compared with routine treatment only.

    In plain wordsIn people with a COPD flare-up, thymosin alpha‑1 added to routine care raised blood oxygen pressure more than routine care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseArterial partial pressure of oxygen (PaO2)
    Study

    n: not reported in source

    Comparator
    Routine treatment only
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated

    Measurements

    MD
    7.24
    PaO2

    Source sentences

    Summary
    increased the arterial partial pressure of oxygen [MD = 7.24, 95% (3.42, 11.07), p = 0.0002]
    1 context sentence
    Summary · context
    Thirty-nine randomised controlled trials with a total of 3,329 patients were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In patients with acute exacerbation of COPD, thymosin alpha‑1 plus routine treatment lowered arterial partial pressure of carbon dioxide compared with routine treatment only.

    In plain wordsIn people with a COPD flare-up, thymosin alpha‑1 added to routine care lowered blood carbon dioxide pressure more than routine care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseArterial partial pressure of carbon dioxide (PaCO2)
    Study

    n: not reported in source

    Comparator
    Routine treatment only
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated

    Measurements

    MD
    −5.85
    PaCO2

    Source sentences

    Summary
    lowered the arterial partial pressure of carbon dioxide [MD = -5.85, 95% (-9.38, -2.33), p = 0.001]
    1 context sentence
    Summary · context
    Thirty-nine randomised controlled trials with a total of 3,329 patients were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In patients with acute exacerbation of COPD, thymosin alpha‑1 plus routine treatment shortened the length of hospital stay compared with routine treatment only.

    In plain wordsIn people with a COPD flare-up, thymosin alpha‑1 added to routine care shortened hospital stay more than routine care alone in pooled trials.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLength of hospital stay
    Study

    n: not reported in source

    Comparator
    Routine treatment only
    Outcome group
    Intensive care and hospital outcomes · Respiratory
    Studied dose
    Dose not stated

    Measurements

    MD
    −5.39
    hospital stay

    Source sentences

    Summary
    shortened the length of hospital stay [MD = -5.39, 95% (-7.82, -2.97), p <0.001]
    1 context sentence
    Summary · context
    Thirty-nine randomised controlled trials with a total of 3,329 patients were included.
  6. 06HumanSystematic reviewEfficacy outcome

    In patients with acute exacerbation of COPD, thymosin alpha‑1 plus routine treatment raised CD4+ T lymphocyte counts compared with routine treatment only.

    In plain wordsIn people with a COPD flare-up, thymosin alpha‑1 added to routine care raised CD4+ immune cell counts more than routine care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+ T lymphocyte count
    Study

    n: not reported in source

    Comparator
    Routine treatment only
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    MD
    7.54
    CD4+ T lymphocytes

    Source sentences

    Summary
    raised the level of CD4+ T lymphocytes count [MD = 7.54, 95%(6.66, 8.41), p <0.001]
    1 context sentence
    Summary · context
    Thirty-nine randomised controlled trials with a total of 3,329 patients were included.
  7. 07HumanSystematic reviewEfficacy outcome

    In patients with acute exacerbation of COPD, thymosin alpha‑1 plus routine treatment raised the CD4+/CD8+ ratio compared with routine treatment only.

    In plain wordsIn people with a COPD flare-up, thymosin alpha‑1 added to routine care raised the CD4+/CD8+ ratio more than routine care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+/CD8+ ratio
    Study

    n: not reported in source

    Comparator
    Routine treatment only
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    MD
    0.4
    CD4+/CD8+

    Source sentences

    Summary
    the ratio of CD4+/CD8+ [MD = 0.40, 95% (0.34, 0.46), p <0.001]
    1 context sentence
    Summary · context
    Thirty-nine randomised controlled trials with a total of 3,329 patients were included.
  8. 08HumanSystematic reviewEfficacy outcome

    In patients with acute exacerbation of COPD, thymosin alpha‑1 plus routine treatment decreased CD8+ T lymphocyte counts compared with routine treatment only.

    In plain wordsIn people with a COPD flare-up, thymosin alpha‑1 added to routine care lowered CD8+ immune cell counts more than routine care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseCD8+ T lymphocyte count
    Study

    n: not reported in source

    Comparator
    Routine treatment only
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    MD
    −2.74
    CD8+ T lymphocytes

    Source sentences

    Summary
    decreased level of CD8+ T lymphocytes count [MD = -2.74, 95% (-3.86, -1.63), p <0.001]
    1 context sentence
    Summary · context
    Thirty-nine randomised controlled trials with a total of 3,329 patients were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.